QTRX vs. TRNS, SENS, CTKB, LAB, ALNT, EYPT, AEHR, QSI, NAUT, and KEQU
Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include Transcat (TRNS), Senseonics (SENS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Allient (ALNT), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Quantum-Si (QSI), Nautilus Biotechnology (NAUT), and Kewaunee Scientific (KEQU). These companies are all part of the "measuring and control equipment" industry.
Quanterix vs.
Quanterix (NASDAQ:QTRX) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation, institutional ownership and community ranking.
In the previous week, Quanterix had 4 more articles in the media than Transcat. MarketBeat recorded 5 mentions for Quanterix and 1 mentions for Transcat. Transcat's average media sentiment score of 1.81 beat Quanterix's score of 0.20 indicating that Transcat is being referred to more favorably in the news media.
Quanterix has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
Transcat has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
86.5% of Quanterix shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 6.9% of Quanterix shares are owned by insiders. Comparatively, 2.3% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Quanterix received 58 more outperform votes than Transcat when rated by MarketBeat users. However, 66.14% of users gave Transcat an outperform vote while only 61.56% of users gave Quanterix an outperform vote.
Quanterix currently has a consensus target price of $23.25, suggesting a potential upside of 207.95%. Transcat has a consensus target price of $111.50, suggesting a potential upside of 39.64%. Given Quanterix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Quanterix is more favorable than Transcat.
Transcat has a net margin of 6.22% compared to Quanterix's net margin of -30.12%. Transcat's return on equity of 7.23% beat Quanterix's return on equity.
Summary
Transcat beats Quanterix on 11 of the 18 factors compared between the two stocks.
Get Quanterix News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quanterix Competitors List
Related Companies and Tools
This page (NASDAQ:QTRX) was last updated on 2/21/2025 by MarketBeat.com Staff
Free QTRX Stock Alerts